 


Steven C. Gilman, Ph.D. :: ContraFect Corporation (CFRX)




























 









NASDAQ: CFRX











Steven C. Gilman, Ph.D.
About Us






Home
About Us
Management Team













	About Us
 










Steven C. Gilman, Ph.D.
Chairman and Chief Executive Officer
Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gilman served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation franchise, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College.
Dr. Gilman currently serves on the board of directors of publicly traded companies Keryx Biopharmaceuticals, Inc., Momenta Pharmaceuticals, Inc., SCYNEXIS Inc, and Vericel Corporation.
Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio. He has authored over 60 publications and is an inventor on 7 patents. 










 

    Steven Gilman | Cubist Pharmaceuticals , Inc. | ZoomInfo.com









Gilman Steven C - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1379970 - Address: 527 Concord, Belmont, MA 02478 39 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


P%ret11102-56-260-6P%wins1001000100060S%ret112-1-5-738569S%wins10010010000050 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



7/26/17 16:427/25/17CFRXContrafect CorpDEHealthDrugPharmaceutical PreparationsGilman Steven CMADOCEOP.d11.2401421D
7/27/16 17:187/27/16CFRXContrafect CorpDEHealthDrugPharmaceutical PreparationsGilman Steven CNYDOCEOP.d502.48020New20D-55-34-40-23-19-11-2202-56-26
10/2/14 16:0710/1/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d3,14765.3904830D
10/2/14 16:0710/1/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-3,14765.390-48-6130D
7/29/14 16:017/28/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d1,02525.2304130D
7/29/14 16:017/28/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-2,50161.570-41-5730D
5/15/14 14:435/14/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.dm25314.3801813930D
5/15/14 14:435/15/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-1,10867.820-16-3530D
5/14/14 16:115/13/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d00.00041429D
5/14/14 16:115/14/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-11669.000-2-529D
2/19/14 15:372/15/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.dm00.00062727D
2/19/14 15:372/18/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-19875.000-3-927D
1/2/14 15:341/2/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.ad46718.69025999%25D
1/2/14 15:341/2/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.ad-1,69567.820-25-5025D
1/2/14 15:151/2/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d46718.69025999%26D
1/2/14 15:151/2/14CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-1,69567.820-25-4926D
6/3/13 18:006/3/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d25316.7601513926D
6/3/13 18:006/3/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-82454.490-15-3726D
5/17/13 12:335/15/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d00.00031126D
5/17/13 12:335/16/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-5948.880-1-426D
5/16/13 15:455/14/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d00.00031125D
5/16/13 15:455/15/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-4948.410-1-425D
5/15/13 17:165/13/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d00.00041823D
5/15/13 17:165/14/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-5649.180-1-523D
2/20/13 11:432/16/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d00.00042221D
2/20/13 11:432/19/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-5141.400-1-621D
1/3/13 13:211/2/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d28018.6901547518D
1/3/13 13:211/2/13CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-64542.980-15-4518D
5/17/12 16:095/17/12CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d37418.6902018D
5/17/12 16:095/17/12CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-83141.570-20-5218D
5/16/12 15:075/14/12CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.dm00.00053718D
5/16/12 15:075/15/12CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.dm-6741.880-2-818D
5/15/12 16:115/13/12CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d00.00043015D
5/15/12 16:115/14/12CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-4741.550-1-715D
10/28/11 12:0010/26/11CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.d1,27117.84337112D1316515141685-20-4-84
10/28/11 12:0010/26/11CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieS.d-2,75838.7033-71-8512D1316515141685-20-4-84
5/17/11 14:555/14/11CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOEVP,ChieM.dm00.003356812D104564553351-1-217-117
5/18/10 13:265/15/10CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOSVP,ChieM.d00.00143816D1430244-7-431-1-6-52856
5/18/10 13:265/17/10CBSTCubist Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsGilman Steven CMAOSVP,ChieS.d-2321.8114-1-166D1430244-7-431-1-6-52856



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.







Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors (NASDAQ:MNTA)

























 






Jun 23, 2016



 Previous Release | Next Release 


PDF

Add to Briefcase
File is in Briefcase



Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors

CAMBRIDGE, Mass., June  23, 2016  (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016.  Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
"Steve brings a strong set of biopharmaceutical research and development expertise and I am very pleased that he has decided to join our Board," said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. "His wealth of experience in building and leading novel immunology and inflammation drug development programs will be of significant importance as we work to rapidly advance our biosimilar and novel autoimmune drug portfolios toward commercialization."   Momenta also announced today that Bennett M. Shapiro, M.D., will no longer serve as a member of Momenta's Board of Directors following completion of his term ending on June 22, 2016.  Dr. Shapiro was a member of the Board of Directors since 
2003, serving on the science, compensation, and nominating and corporate governance committees. "I'd like to thank Ben for his many years of invaluable support in building Momenta into the company it is today with two complex generic products on the market and a robust portfolio of biosimilar and novel drug candidates. We wish him well in his future endeavors," continued Mr. Wheeler. Dr. Gilman currently serves as the Executive Chairman and interim CEO of ContraFect Corporation (NASDAQ:CFRX) and as a member of the board of directors of Vericel (NASDAQ:VCEL), SCYNEXIS (NASDAQ:SCYX) and 
Keryx (NASDAQ:KERX). He also serves as a member of the board of directors of the Northeastern University Drug Discovery Advisory Board, the Massachusetts Biotechnology Association and the Penn State University Biotechnology Advisory Board. Prior to joining Cubist, Dr. Gilman served as Chairman of the Board of Directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation Franchise. Prior to Millennium, he was Group Director at Pfizer Central Research, where he was responsible for drug discovery of novel antibacterial agents as well 
as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple University School of Medicine, and Connecticut College. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio. About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is 
headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their 
respective owners. Forward Looking Statements Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Dr. Gilman benefitting the Company; advancing our product pipeline; and bringing multiple products to market in the coming years.  Forward-looking statements may be identified by words such as "will," "work" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the 
Company's Quarterly Report on Form 10-Q for the month ended March 31, 2016, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  
INVESTOR CONTACT:

Sarah Carmody

Momenta Pharmaceuticals

1-617-395-5189

IR@momentapharma.com



MEDIA CONTACT:

Karen Sharma

MacDougall Biomedical Communications

1-781-235-3060

Momenta@macbiocom.com





Source: Momenta Pharmaceuticals, Inc.

News Provided by Acquire Media








 

Steven C. Gilman Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 6:08 PM ET
Biotechnology

Company Overview of ContraFect Corporation



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Steven C. Gilman Ph.D.Executive Chairman, Chief Executive Officer and President, ContraFect CorporationAgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 8 different industries.See Board Relationships64$1,159,597As of Fiscal Year 2016
Background

		Dr. Steven C. Gilman, also known as Steve, Ph.D., has been the Chief Executive Officer and President of ContraFect Corporation since July 21, 2016 and as its Executive Chairman since May 20, 2015. Dr. Gilman is on Leave of Absence. Dr. Gilman served as an Interim Chief Executive Officer of ContraFect Corporation from March 21, 2016 to July 21, 2016. Dr. Gilman served as the Chief Scientific Officer at Cubist Pharmaceuticals Inc. since February 2008 and served as its ... Executive Vice President of Research & Development since September 2010. He has more than 28 years of drug research and development experience. He served as a Senior Vice President of Discovery & Non Clinical Development at Cubist Pharmaceuticals Inc. from February 2008 to September 2010. He served as the Chairman of the Board of ActivBiotics, Inc. from May 1, 2007 to February 2008 and also as its Chief Executive Officer from March 2004 to February 2008 and President from March 2004 to May 1, 2007. He served as the Chief Executive Officer and President of ActivBiotics Canada Inc., a subsidiary of ActivBiotics, Inc. While at ActivBiotics, he led the transition of the ActivBiotics from early research/academic stage to focus on advanced product development and commercialization. He served as Vice President and General Manager of Inflammation Franchise of Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation Franchise. He served as Group Director of Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. He was responsible for pharmaceutical research units at Sterling Winthrop and Wyeth Laboratories in areas including chronic inflammatory diseases, transplant rejection, autoimmune diseases and bacterial infections. He has been a Director of Momenta Pharmaceuticals Inc. since June 22, 2016. He has been an Independent Director of Keryx Biopharmaceuticals Inc. since April 1, 2016, SCYNEXIS, Inc. since February 25, 2015 and Vericel Corporation since January 2015. He has been a Director of ContraFect Corporation since May 20, 2015. He serves on the Biotechnology Advisory Board of Penn State University. He serves on director of the Massachusetts Biotechnology Council and Nextcea, Inc. He serves as a Director of the Northeastern University Drug Discovery Advisory Board. He served as a Director of Inhibikase Therapeutics, Inc. from May 2011 to January 8, 2016. He served as a Director of ActivBiotics, Inc. since March 2004. Dr. Gilman received his B.A. degree from Miami University (Ohio) and his M.S. and Ph.D. degrees in Microbiology from Pennsylvania State University. He completed a Post-Doctoral Research Fellowship in the Department of Immunopathology at the Scripps Clinic and Research Foundation.Read Full Background




Corporate Headquarters
28 Wells AvenueYonkers, New York 10701United StatesPhone: 914-207-2300Fax: --
Board Members Memberships
2015-PresentIndependent DirectorVericel Corporation2015-PresentIndependent DirectorSCYNEXIS, Inc.2015-PresentExecutive Chairman, Chief Executive Officer and PresidentContraFect Corporation2016-PresentIndependent DirectorKeryx Biopharmaceuticals, Inc.2016-PresentDirectorMomenta Pharmaceuticals, Inc.
Education
MS Pennsylvania State UniversityPhD Pennsylvania State UniversityBA Miami University
Other Affiliations
Vericel CorporationCubist Pharmaceuticals LLCKeryx Biopharmaceuticals, Inc.SCYNEXIS, Inc.ActivBiotics, Inc.Pennsylvania State UniversityMiami UniversityMomenta Pharmaceuticals, Inc.ActivBiotics Canada Inc.Inhibikase Therapeutics, Inc


Annual Compensation
Salary$409,792Bonus$131,250Total Annual Compensation$541,042
Stocks Options
All Other Compensation$17,748Exercisable Options$182,500Unexercisable Options$107,500Total Number of Options$290,000
Total Compensation
Total Annual Cash Compensation$1,002,540Total Short Term Compensation$541,042Other Long Term Compensation$17,748Total Calculated Compensation$1,159,597




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact ContraFect Corporation, please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close



































Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. To Board Of Directors - Pg.2 - TheStreet





































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. To Board Of Directors






GlobeNewswire



Jun 23, 2016 8:00 AM EDT













 


















































 Prior to joining Cubist, Dr. Gilman served as Chairman of the Board of Directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation Franchise. Prior to Millennium, he was Group Director at Pfizer Central Research, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple University School of Medicine, and Connecticut College. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.   About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. To receive additional information about Momenta, please visit the website at  www.momentapharma.com, which does not form a part of this press release. Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.  Forward Looking Statements Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Dr. Gilman benefitting the Company; advancing our product pipeline; and bringing multiple products to market in the coming years.  Forward-looking statements may be identified by words such as "will," "work" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the month ended March 31, 2016, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  



 








 










































If you liked this article you might like













Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..



William McConnell

Jun 13, 2017 12:07 PM EDT
























Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More
Here are Wednesday's top research calls, including downgrades for Discovery, First Solar and Momenta, and an upgrade for VF Corp.



TheStreet Staff

Feb 22, 2017 8:03 AM EST
























Sarepta Leads Biotech Movers on Voucher Deal News
Gilead (finally!) has acquired something from Sarepta, even if it is quite small.



Alicia McElhaney

Feb 21, 2017 10:09 AM EST
























Mylan's Shares Rise Despite FTC Investigation
The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.



Alicia McElhaney

Jan 31, 2017 11:16 AM EST








































 











Trending


How Amazon Billionaire Jeff Bezos Gained Vast Riches and a Tech Giant Someday Worth $1 Trillion


Jim Cramer Nails Starbucks' Big Decline, Warns Again of Downside to $50


Here's Why Snap's Stock Could Be In For Another Big Plunge on Monday


Tesla's Model 3 Arrives on Friday -- Here's Everything You Need to Know About This Over-Hyped Ride


iPod Nano, Shuffle Are Dead; Here Are 8 Other Discontinued Apple Products











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft









ContraFect Chairman Steven C. Gilman Returns from Temporary Medical LeaveHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets closedS&P 5002,472.10-3.32 (-0.13%)Dow 3021,830.31+33.76 (+0.15%)Nasdaq6,374.68-7.51 (-0.12%)LISTENWho is the face of pro baseball?Yahoo Finance's Dan Roberts and Myles Udland debate the business of baseballContraFect Chairman Steven C. Gilman Returns from Temporary Medical LeaveMarketwiredMay 30, 2017ReblogShareTweetShareYONKERS, NY--(Marketwired - May 30, 2017) - ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Chairman of ContraFect's Board of Directors, intends to return from his temporary medical leave to resume his role as Chief Executive Officer on June 1, 2017."I want to thank the Company's senior management team for maintaining focus and momentum during my temporary leave. I look forward to resuming my duties as CEO and helping to advance ContraFect's mission to provide important new therapies for patients with life-threatening infectious diseases," said Dr. Gilman.About ContraFectContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to drug-resistant bacterial infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). In addition to CF-301, the company's preclinical programs include potential novel lysins for the treatment of drug resistant gram-negative pathogens as well as a monoclonal antibody program targeted for the treatment of viral influenza.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "can," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods, and include statements in this release regarding our ability to address life threatening infections using our therapeutic product candidates from our lysin and antibody platforms by targeting conserved regions of either bacteria or viruses, our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, Dr. Gilman's intent to return from his medical leave on June 1, 2017 and advancing ContraFect's mission. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including the effects, progress and outcomes of Dr. Gilman's medical treatments and the other important factors detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextFinish your antibiotics course? Maybe not, experts sayAFPThis Will Be In Everyone's Household By 2020Banyan HillSponsoredChild Born with HIV is Virtually Virus-Free for 9 Years, Without MedsLiveScience.comTrump names John Kelly new chief of staff; Reince Priebus outCNBCThe 'two pizza rule' is a secret to productive meetings that helped Amazon CEO Jeff Bezos become one of the world's richest menBusiness InsiderEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredNorth Korea 2nd ICBM test puts much of US in range: expertsAssociated PressChevron and Exxon Mobil have a tough path ahead: NYSE traderYahoo Finance VideoStocks mixed after heavy earnings weekProtect Your New Galaxy S8SamsungSponsoredThe real reason overseas manufacturing is coming to AmericaYahoo FinanceHere are the US targets North Korea most likely wants to nukeBusiness InsiderTax cuts just got more likelyYahoo FinanceZuckerberg Wife's Ambitious Secret Finally ExposedUNewz.MeSponsoredMy bullish view on stocks hasn't changed one iota: NYSE traderYahoo Finance VideoBlue Apron: Bullish calls not all they're cooked up to beYahoo FinanceDonald Trump Tweet-Rages After John McCain Kills Obamacare Skinny RepealStan: Let trump rage.  McCain you did the right thing.Join the Conversation1 / 51.4k








Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors – PM360       NASDAQMomenta Pharmaceuticals Appoints Steven C. ...Linkedin 0Cancer Genetics, Inc. and Sayre ...type in your search and press enter      NASDAQ Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of DirectorsNASDAQNASDAQ Oncology Market NewsMomenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors     byNASDAQ Market NewsJune 23, 2016      Facebook Twitter Linkedin Linkedin0Shares CAMBRIDGE, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016.  Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015. "Steve brings a strong set of biopharmaceutical research and development expertise and I am very pleased that he has decided to join our Board," said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “His wealth of experience in building and leading novel immunology and inflammation drug development programs will be of significant importance as we work to rapidly advance our biosimilar and novel autoimmune drug portfolios toward commercialization.”   Momenta also announced today that Bennett M. Shapiro, M.D., will no longer serve as a member of Momenta’s Board of Directors following completion of his term ending on June 22, 2016.  Dr. Shapiro was a member of the Board of Directors since 2003, serving on the science, compensation, and nominating and corporate governance committees. "I'd like to thank Ben for his many years of invaluable support in building Momenta into the company it is today with two complex generic products on the market and a robust portfolio of biosimilar and novel drug candidates. We wish him well in his future endeavors," continued Mr. Wheeler. Dr. Gilman currently serves as the Executive Chairman and interim CEO of ContraFect Corporation (NASDAQ:CFRX) and as a member of the board of directors of Vericel (NASDAQ:VCEL), SCYNEXIS (NASDAQ:SCYX) and Keryx (NASDAQ:KERX). He also serves as a member of the board of directors of the Northeastern University Drug Discovery Advisory Board, the Massachusetts Biotechnology Association and the Penn State University Biotechnology Advisory Board. Prior to joining Cubist, Dr. Gilman served as Chairman of the Board of Directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation Franchise. Prior to Millennium, he was Group Director at Pfizer Central Research, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple University School of Medicine, and Connecticut College. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio. About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release. Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners. Forward Looking Statements Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Dr. Gilman benefitting the Company; advancing our product pipeline; and bringing multiple products to market in the coming years.  Forward-looking statements may be identified by words such as "will," "work" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the month ended March 31, 2016, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  CONTACT: INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com

MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Facebook Twitter Linkedin Linkedin0Shares NASDAQ Market NewsClick here to email authorNEXT STORYCancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI’s Proprietary FDA-cleared Tissue of Origin (TOO®) Test Throughout India and South AsiaPREV STORYInvestigational Wnt inhibitor shows promise in knee osteoarthritisSubscribe to PM360Follow UsExperts on CallBrenda SnowAuthentic Patient VoiceAmy GroggRare Disease & Orphan Drug Commercialization John Weinman, PhDHealth PsychologyRichard MeyerDTC MarketingChris DowdPatient LoyaltyDon FeilerBrand EngagementRick RatliffEMR/EHR ConnectionsJeffrey D. ErbLife Sciences Medical Strategy Erik DaltonHCP EngagementJessica BrueggemanPatient-Provider DialogueBud BilanichSuccess Coach Get in touch with PM360 Experts On CallAdsYou May Also LikeNASDAQNASDAQ Mental Health Market NewsDoctors Administrative Solutions acquires ConXit Technology Group; forms national Health IT & management solutions firm: DAS HealthTampa, Fla., Jan. 04, 2016 (GLOBE NEWSWIRE) -- United by a common business culture, ...NASDAQ Market NewsJanuary 8, 2016NASDAQNASDAQ Mental Health Market NewsLightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of PennsylvaniaNEW YORK, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a ...NASDAQ Market NewsJanuary 8, 2016NASDAQNASDAQ Mental Health Market NewsCareSource Foundation Awards $1.6 Million to Ohio Nonprofit Organizations in 2015DAYTON, Ohio, Dec. 21, 2015 (GLOBE NEWSWIRE) -- The CareSource Foundation has announced the ...NASDAQ Market NewsJanuary 8, 2016     ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive OfficerHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets closedS&P 5002,472.10-3.32 (-0.13%)Dow 3021,830.31+33.76 (+0.15%)Nasdaq6,374.68-7.51 (-0.12%)LISTENWho is the face of pro baseball?Yahoo Finance's Dan Roberts and Myles Udland debate the business of baseballContraFect Corporation Names Steven C. Gilman, PhD Chief Executive OfficerMarketwiredJuly 21, 2016ReblogShareTweetShareYONKERS, NY--(Marketwired - July 21, 2016) - ContraFect Corporation (CFRX) (CFRXW) ("ContraFect," "we," or the "Company"), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has named Steven C. Gilman, PhD, as Chief Executive Officer of ContraFect, effective immediately. Dr. Gilman has served as Interim Chief Executive Officer since March 21, 2016. He will continue to serve as Chairman of the Board of Directors of the Company."The Board is pleased to have an executive with the experience and credentials of Steve Gilman to serve as Chief Executive Officer at ContraFect," said Sol Barer, ContraFect's Lead Independent Director. "Steve is a proven leader in the infectious disease field, and has extensive experience in the development and commercialization of new anti-infective agents.""In my time as Interim Chief Executive Officer I have worked closely with our team and am excited at the opportunity to bring forward the programs at ContraFect and support the company's mission of creating new treatments for life-threatening infectious diseases," said Dr. Gilman.About ContraFect: ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza.FORWARD-LOOKING STATEMENTS This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this press release include, without limitation, statements regarding Dr. Gilman's opportunity to bring forward ContraFect's programs and support the company's mission, and the Company's intention to address life-threatening conditions using product candidates from its lysin and monoclonal antibody platforms. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation: the Company has incurred significant losses since its inception and may never achieve profitability; the Company's recurring losses from operations could raise substantial doubt regarding its ability to continue as a going concern; the Company has no product revenues; the Company's short operating history; the Company's need for substantial additional funding; the Company may be required to suspend or discontinue clinical trials due to adverse side effects or other safety risks; clinical trials of the Company's product candidates are subject to delays, which could result in increased costs and jeopardize its ability to obtain regulatory approval and commence product sales as currently contemplated; the Company's dependence on its license agreements with Rockefeller that relate to CF-301; the Company's dependence on clinical research organizations; the Company's lack of experience in bringing a drug to regulatory approval; the Company's ability to obtain regulatory approval of and commercialize its product candidates; the Company's ability to attract and retain qualified personnel, and changes in management; difficulties in managing the Company's growth; and the important factors described under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 10, 2016 and its other filings with the SEC. Any forward-looking statement made by the Company in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Read MoreThe Company has filed a registration statement (including the Preliminary Prospectus) with the Securities and Exchange Commission (the "SEC") for an offering of its common stock and warrants. Before you invest in that offering, you should read the Preliminary Prospectus in that registration statement for more complete information about the Company and the offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a copy of the Preliminary Prospectus may be obtained from the offices of: Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924 or by email: prospectuspjc.com. You may obtain a copy of the Preliminary Prospectus at https://www.sec.gov/Archives/edgar/data/1478069/000119312516653739/0001193125-16-653739-index.htm.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextMeg Whitman's out. Will GE chief executive take over Uber?SiliconBeatThis Will Be In Everyone's Household By 2020Banyan HillSponsoredWind Projects in Peril as Indian States Rethink PurchasesBloombergAmazon Surpasses $500B Mark, Bezos Briefly Becomes the World’s Richest PersonInvestopediaMy next car is electrified, says Shell CEOAutoblogEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredWhat you need to know on Wall Street todayBusiness InsiderTrump names John Kelly new chief of staff; Reince Priebus outCNBCThe 'two pizza rule' is a secret to productive meetings that helped Amazon CEO Jeff Bezos become one of the world's richest menBusiness InsiderZuckerberg Wife's Ambitious Secret Finally ExposedUNewz.MeSponsoredNorth Korea 2nd ICBM test puts much of US in range: expertsAssociated PressAll the companies in Jeff Bezos’s empire, in one (large) chartMarketWatchChevron and Exxon Mobil have a tough path ahead: NYSE traderYahoo Finance VideoDiscover it: 4.8 out of 5 avg. by 24K+ customersDiscover CardSponsoredStocks mixed after heavy earnings weekThe real reason overseas manufacturing is coming to AmericaYahoo FinanceDonald Trump Tweet-Rages After John McCain Kills Obamacare Skinny RepealStan: Let trump rage.  McCain you did the right thing.Join the Conversation1 / 51.4k








